GLSI
NASDAQ · Biotechnology
Greenwich Lifesciences Inc
$26.81
+1.13 (+4.40%)
Open$25.91
Previous Close$25.68
Day High$27.21
Day Low$25.90
52W High$34.10
52W Low$7.78
Volume—
Avg Volume235.0K
Market Cap358.56M
P/E Ratio—
EPS$-1.46
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+27.0% upside
Current
$26.81
$26.81
Target
$34.05
$34.05
$25.54
$34.05 avg
$45.13
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 64.12M | 62.89M | 59.76M |
| Net Income | 10.06M | 8.97M | 9.50M |
| Profit Margin | 15.7% | 14.3% | 15.9% |
| EBITDA | 19.32M | 16.62M | 17.12M |
| Free Cash Flow | 7.72M | 11.60M | 9.03M |
| Rev Growth | -9.0% | -7.6% | +0.6% |
| Debt/Equity | 0.70 | 0.55 | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |